telehealth adhd prescriptions after december 31, 2026: what is allowed now, what is pending, and what changes if it lapses

if your adhd prescription comes through a video visit with someone you have never met in a room, the permission that makes that legal has an end date printed in the federal register: the end of the day on december 31, 2026.

this page is what the documents say as of october 23, 2026: the rule in force now and its citation, the final rule that is pending and where it sits, what the law requires if nothing replaces the current rule, the separate permanent rule for buprenorphine, and the questions worth asking a prescriber before december. no predictions. when the final rule publishes, this page changes that day.

what is allowed right now, and the citation

the rule in force is the fourth temporary extension of covid-19 telemedicine flexibilities for prescription of controlled medications, published by dea and hhs on december 31, 2025 at 90 fr 61301 (fr doc. 2025-24123), effective january 1 through december 31, 2026^[1]. its operative sentence, in 21 cfr 1307.41(b): during the period through december 31, 2026, “a dea-registered practitioner is authorized to prescribe schedule ii-v controlled substances via telemedicine … to a patient without having conducted an in-person medical evaluation of the patient” if four conditions are met. the prescription has a legitimate medical purpose in the usual course of practice; it comes from a live interactive telecommunications system (the rule points to the medicare definition in 42 cfr 410.78(a)(3)); the practitioner's registration covers that schedule; and the prescription meets every other dea prescription rule^[1]. the same paragraph says the authorization “expires at the end of december 31, 2026.”

this is the fourth time the deadline has moved. the first extension (may 2023) ran to november 11, 2023; the second (october 2023) to december 31, 2024; the third (november 2024) to december 31, 2025; the fourth to december 31, 2026^[1],[5]. dea's stated reason each time is what it calls the “telemedicine cliff”: the abrupt return of pre-pandemic restrictions before a permanent rule exists^[1].

how many prescriptions ride on it

dea does not publish its own count. the december 2025 rule quotes a stakeholder's summary of unpublished electronic-record data: of an estimated 44.6 million controlled substance prescriptions across 258 organizations in 2024, more than 7 million, about 16 percent, were issued without a prior in-person evaluation^[1]. as a preview of a lapse, the rule cites what happened when medicare's separate telehealth flexibilities lapsed on september 30, 2025: a 24 percent drop in fee-for-service telemedicine visits in the following 17 days, nearly 40 percent or more in several states^[1]. both figures are the agency's case for extending, not an independent audit; they are on this page because they are the only numbers in the record.

where the permanent rule is

congress told dea in 2008 to create a special registration for telemedicine, and the 2018 support act set a statutory deadline of october 2019; dea's own agenda still lists that deadline^[5]. the proposal arrived on january 17, 2025: special registrations for telemedicine and limited state telemedicine registrations, 90 fr 6541, rin 1117-ab40^[3]. dea reports more than 6,475 comments on it^[1].

the final rule reached the office of information and regulatory affairs, the white house office that reviews significant rules before publication, on august 25, 2026. on october 23, 2026 the review dashboard lists it as a final rule, economically significant, status pending review^[4]. the current unified agenda gives its planned date as “11/00/2026,” meaning sometime in november^[5]. a federal register search the same day found no final rule and no fifth extension. two cautions: an agenda date is a plan (the previous agenda said december 2025, and an extension came instead), and the text under review is not public, so anyone describing what the final rule says before it publishes is guessing^[4],[5].

what the proposal said about adhd stimulants

this is the 2025 proposal, not the final rule, and the final rule can differ in any part^[3]. it proposed three registrations: a telemedicine prescribing registration for schedule iii to v drugs; an advanced telemedicine prescribing registration for schedule ii to v, limited to specialised clinicians (its examples are psychiatrists and hospice physicians); and a registration for telemedicine platforms. schedule ii is where the adhd stimulants sit, and for schedule ii the proposal added two limits that dea said it was considering imposing “one or both” of^[3]:

• the prescriber would have to be physically located in the same state as the patient when issuing a schedule ii telemedicine prescription;
• telemedicine schedule ii prescriptions would have to be less than 50 percent of the prescriber's total schedule ii prescriptions in a calendar month.

it also proposed a nationwide prescription drug monitoring program check before prescribing, with that requirement delayed three years and state-level checks in the meantime^[3]. if those limits survive, the question for a patient becomes whether their prescriber holds the advanced registration, sits in their state, and keeps enough in-person schedule ii practice. if they do not survive, the change is smaller. nobody outside the review knows which.

what changes for a patient if it lapses

if december 31 passes with no final rule in effect and no fifth extension, the flexibilities end and the statute governs. 21 u.s.c. 829(e) says a controlled substance that is a prescription drug may not be dispensed by means of the internet without a “valid prescription,” defined as one issued for a legitimate medical purpose by “a practitioner who has conducted at least 1 in-person medical evaluation of the patient” or by a covering practitioner^[2]. an in-person evaluation is one “conducted with the patient in the physical presence of the practitioner.” the law carries seven narrow telemedicine exceptions in 21 u.s.c. 802(54), such as a patient being treated inside a dea-registered hospital or clinic^[1],[2].

the part most people miss is in dea's own rule. once a practitioner has conducted at least one in-person evaluation of a particular patient, the remote-prescribing requirements “no longer apply to that specific practitioner-patient relationship,” and the practitioner may prescribe remotely “indefinitely, regardless of how much time has passed since the initial in-person medical evaluation or whether that evaluation was for a separate medical concern”^[1]. so the people a lapse would hit are the ones whose prescriber has never been in a room with them: patients whose care with that prescriber began, and has stayed, on video.

three things a lapse would not change. non-controlled medicines are outside the ryan haight act entirely: atomoxetine and guanfacine, the non-stimulant adhd options, are not controlled substances, while lisdexamfetamine is schedule ii^[2],[9]. inside the va, a separate final rule lets a va practitioner prescribe by telemedicine if any va practitioner has seen the patient in person^[8]. and the buprenorphine rule below is permanent.

buprenorphine has its own permanent rule

on january 17, 2025 dea and hhs published expansion of buprenorphine treatment via telemedicine encounter, 90 fr 6504, adding 21 cfr 1306.51^[6]. after two delays it took effect on december 31, 2025 (90 fr 13410); a federal register search on october 23, 2026 found no later delay^[7]. under it, after reviewing the prescription drug monitoring program data for the state the patient is in, a practitioner may prescribe an initial six-month supply of a schedule iii to v medication approved for opioid use disorder by telemedicine, including audio-only, split across several prescriptions; the pharmacist must verify the patient's identity; prescriptions after the six months need another form of telemedicine the law allows or an in-person evaluation^[6]. through 2026 a prescriber can use either this rule or the broader temporary one, which has fewer requirements^[1]. after 2026 this rule stays. it does nothing for schedule ii drugs.

a separate thing at the same office: stimulant supply

the same review dashboard lists a dea notice adjusting the 2026 aggregate production quotas for d,l-amphetamine, d-amphetamine and methylphenidate, received october 14, 2026^[4]. production quotas govern how much of a schedule ii drug may be made in a year; they are about supply, not about who may prescribe by video. the notice text is not public until it publishes.

what to ask your prescriber now

these are questions, not advice. they are the ones the documents above make it reasonable to ask.

• have you ever evaluated me in person, and if so, does your practice count that as meeting the ryan haight requirement for us?
• if the flexibilities end on december 31 without a replacement, what is your plan for patients you have only seen by video, and would i need an in-person visit, where and by when?
• are you planning to apply for a dea special registration once the final rule is out, and are you in the same state as me?
• if my prescriber changes, for example to a covering clinician, does the new prescriber need their own in-person visit with me?
• if i am treated for opioid use disorder, which rule are my prescriptions written under, and what happens at the six-month point?
• if a gap in prescribing did happen, what should i know about stopping a stimulant or buprenorphine suddenly, and who would i contact?

adam